ENBBF - My Dividend Growth Portfolio: Selling Bio-Pharma And Buying More Big-Tech
2024-05-13 04:06:09 ET
Summary
- I have been focused on accumulating shares of blue chip compounders with market-beating returns and increasing passive income.
- I have reduced my holding count from 85 stocks/funds to 70 and have become more concentrated in my highest conviction ideas.
- I have shifted my strategy to focus on quality rather than value and have been buying big-tech stocks with secular tailwinds.
It’s been a little while since I’ve published a portfolio review, but in recent months, I’ve continued to take strides reshaping my portfolio into my desired long-term form, so I wanted to take some time this week to provide an update for everyone.
In short, I’ve been intensely focused on accumulating shares of blue chip compounders with the potential to produce market-beating returns while providing a reliably increasing passive income stream over the past year or so… and that trend continues.
Coming into the year I wrote about my desire to simplify things a bit, reducing my position count, and getting more concentrated into my highest conviction ideas. In doing so, I said I would be cutting ties with low-growth deep value trades and focus more of my attention on the highest quality compounders (even if that meant paying a relative premium for shares)....
My Dividend Growth Portfolio: Selling Bio-Pharma And Buying More Big-Tech